Chikungunya is a viral disease primarily transmitted to humans by infected female mosquitoes, specifically the Aedes aegypti and Aedes albopictus species. The name “chikungunya” originates from the Kimakonde language, meaning “to become contorted” describing the stooped appearance of individuals suffering from joint pain, a characteristic symptom of the disease.
The chikungunya virus (CHIKV) belongs to the alphavirus genus of the Togaviridae family. It was first identified in Tanzania in 1952 during an outbreak in Makonde village. Since then, chikungunya has spread to many countries in Africa, Asia, Europe, and the Americas.
Epidemiology
Chikungunya is considered an endemic disease in several regions of Africa, Asia, and the Indian subcontinent. The virus circulates in these areas, and outbreaks occur periodically. The prevalence of chikungunya can vary from year to year and from region to region within endemic areas. Sporadic or small outbreaks may occur in non-endemic regions due to travel or locally transmitted cases.
Chikungunya outbreaks can result in many cases within a short period. During outbreaks, the incidence can vary widely, ranging from a few cases to thousands or even tens of thousands of cases, depending on the size and vulnerability of the affected population. Chikungunya is generally considered a non-fatal disease; most infected individuals recover fully.
The mortality rate associated with chikungunya is relatively low, especially compared to other mosquito-borne diseases such as dengue or malaria. However, severe cases and complications can occur, particularly among vulnerable populations such as infants, older adults, and individuals with pre-existing health conditions. Mortality rates are typically highest during large-scale outbreaks, and the overall mortality burden remains relatively low compared to other infectious diseases.
Anatomy
Pathophysiology
Chikungunya virus is primarily transmitted to humans through the bite of infected female mosquitoes. After entering the body, the virus targets and infects the skin, lymphoid tissue, and joint cells. The viral particles bind to specific receptors on the surface of host cells, allowing entry and subsequent replication of the virus. Following the initial infection, the virus can disseminate within the body through the bloodstream, reaching various tissues and organs. This dissemination can lead to systemic symptoms and the involvement of multiple systems.
The immune system plays a crucial role in the pathophysiology of chikungunya. The initial immune response involves the activation of innate immune cells, such as macrophages and dendritic cells, which recognize the viral particles and produce pro-inflammatory cytokines. This immune response helps control viral replication and contributes to the inflammatory process and associated symptoms. The immune response triggers an intense inflammatory reaction characterized by releasing pro-inflammatory mediators and chemokines.
This inflammatory response is responsible for many clinical manifestations observed in chikungunya, such as joint pain, swelling, and fever. The immune cells, and macrophages, infiltrate the affected tissues, contributing to the inflammatory process. Chikungunya is well known for causing severe joint pain and arthritis. The exact mechanisms underlying joint involvement are not fully understood, but it is believed to involve a combination of direct viral replication in joint tissues and immune-mediated inflammation. The synovial membrane, cartilage, and surrounding tissues can be affected, leading to joint swelling, stiffness, and pain.
Etiology
The etiology of chikungunya is attributed to the chikungunya virus (CHIKV), which is a single-stranded RNA virus belonging to the Alphavirus genus of the Togaviridae family. The virus is primarily transmitted to humans through the bite of infected mosquitoes, particularly Aedes aegypti and Aedes albopictus species.
The natural transmission cycle of CHIKV involves mosquitoes as the primary vector and vertebrate hosts, including humans, as the reservoirs. The virus is maintained in nature through cycles of mosquito-human-mosquito transmission. Apart from mosquito-borne transmission, other modes of CHIKV transmission have been reported, although they are relatively rare.
These include vertical transmission from infected mother to fetus during pregnancy, transmission through blood transfusion, and laboratory-acquired infections. Chikungunya outbreaks can occur where appropriate mosquito vectors are present, creating favorable conditions for viral transmission. Factors such as high population density, urbanization, inadequate mosquito control measures, and climate change can contribute to chikungunya’s increased risk and spread.
Genetics
Prognostic Factors
The prognosis of chikungunya is generally good, and most individuals recover fully within weeks to months. Most chikungunya infections do not result in severe complications or long-term health issues.
Clinical History
Clinical History
Many individuals with chikungunya develop a maculopapular rash characterized by small, red spots or bumps on the skin. The rash often starts on the trunk and limbs and may spread to the face and extremities. It is usually itchy and can last for a few days to weeks. Severe joint pain is a hallmark of chikungunya. The pain typically affects multiple joints symmetrically, such as the wrists, fingers, ankles, and knees.
The pain may be debilitating and can last for weeks or months, occasionally becoming chronic. The joints may also appear swollen and tender. Headaches are a frequent symptom of chikungunya and may be severe and debilitating. They can occur in conjunction with fever and other systemic manifestations. Individuals with chikungunya commonly experience fatigue and malaise. Patients may feel exhausted, weak, and have decreased energy.
Physical Examination
Physical Examination
Joint tenderness, swelling, and restricted range of motion may be observed during a joint examination. Multiple joints, such as wrists, fingers, ankles, and knees, may be affected symmetrically. The severity of joint involvement can vary, ranging from mild to severe. A maculopapular rash may be present on the skin.
The rash is characterized by small, red spots or bumps that can be itchy and may be distributed on the trunk, limbs, face, and extremities. Palpation of muscles may reveal tenderness, particularly in areas where the patient experiences myalgia. Swollen and tender lymph nodes may be observed during palpation, typically in regions close to the affected joints or the neck area. In some cases, there may be redness and inflammation of the conjunctiva, the thin membrane covering the white part of the eye.
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Differential Diagnoses
African tick bite fever
Malaria
Yellow Fever
Measles
Leptospirosis
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
The primary approach to treating Chikungunya fever focuses on relieving symptoms. This includes ensuring adequate hydration, rest and using medications such as acetaminophen for pain and fever relief. It is important to note that aspirin and most NSAIDs are generally discouraged during the initial 48 hours of symptom onset, as they can potentially worsen platelet dysfunction, mainly if there is a possibility of dengue virus co-infection.
The World Health Organization recommends avoiding these medications during this period. Some studies suggest that low-dose corticosteroid drugs may effectively manage symptoms during the first two months of the post-acute phase. Treatment options for ocular manifestations, such as anterior and posterior uveitis, include topical steroids and cycloplegics. These interventions can help alleviate inflammation and provide relief.
Persistent or recurrent symptoms in the chronic phase of Chikungunya, such as long-lasting joint pain (polyarthralgia), joint inflammation (polyarthritis), and muscle pain (myalgia), have shown positive responses to treatment with hydroxychloroquine when combined with corticosteroids or other disease-modifying anti-rheumatic drugs (DMARDs). Hydroxychloroquine, along with additional medications, helps alleviate these chronic manifestations.
In terms of antiviral treatments, specific antivirals that target viral replication by utilizing small interfering RNAs (siRNAs) and inhibit virus entry and replication have demonstrated promising results. However, it is important to note that these antiviral treatments have yet to receive approval for human use, and further research is needed to establish their safety and effectiveness.
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
Future Trends
Media Gallary
References
News
Rare Uterine Lipoma Diagnosed Post-Surgery: Case Report
Posted on
News
Robotic Breakthrough in Brain Surgery
Posted on
News
Bangladesh Achieves Remarkable Reduction in Lead in Turmeric
Posted on
News
Suppressing Negative Thoughts Can Improve Mental Health
Chikungunya is a viral disease primarily transmitted to humans by infected female mosquitoes, specifically the Aedes aegypti and Aedes albopictus species. The name “chikungunya” originates from the Kimakonde language, meaning “to become contorted” describing the stooped appearance of individuals suffering from joint pain, a characteristic symptom of the disease.
The chikungunya virus (CHIKV) belongs to the alphavirus genus of the Togaviridae family. It was first identified in Tanzania in 1952 during an outbreak in Makonde village. Since then, chikungunya has spread to many countries in Africa, Asia, Europe, and the Americas.
Chikungunya is considered an endemic disease in several regions of Africa, Asia, and the Indian subcontinent. The virus circulates in these areas, and outbreaks occur periodically. The prevalence of chikungunya can vary from year to year and from region to region within endemic areas. Sporadic or small outbreaks may occur in non-endemic regions due to travel or locally transmitted cases.
Chikungunya outbreaks can result in many cases within a short period. During outbreaks, the incidence can vary widely, ranging from a few cases to thousands or even tens of thousands of cases, depending on the size and vulnerability of the affected population. Chikungunya is generally considered a non-fatal disease; most infected individuals recover fully.
The mortality rate associated with chikungunya is relatively low, especially compared to other mosquito-borne diseases such as dengue or malaria. However, severe cases and complications can occur, particularly among vulnerable populations such as infants, older adults, and individuals with pre-existing health conditions. Mortality rates are typically highest during large-scale outbreaks, and the overall mortality burden remains relatively low compared to other infectious diseases.
Chikungunya virus is primarily transmitted to humans through the bite of infected female mosquitoes. After entering the body, the virus targets and infects the skin, lymphoid tissue, and joint cells. The viral particles bind to specific receptors on the surface of host cells, allowing entry and subsequent replication of the virus. Following the initial infection, the virus can disseminate within the body through the bloodstream, reaching various tissues and organs. This dissemination can lead to systemic symptoms and the involvement of multiple systems.
The immune system plays a crucial role in the pathophysiology of chikungunya. The initial immune response involves the activation of innate immune cells, such as macrophages and dendritic cells, which recognize the viral particles and produce pro-inflammatory cytokines. This immune response helps control viral replication and contributes to the inflammatory process and associated symptoms. The immune response triggers an intense inflammatory reaction characterized by releasing pro-inflammatory mediators and chemokines.
This inflammatory response is responsible for many clinical manifestations observed in chikungunya, such as joint pain, swelling, and fever. The immune cells, and macrophages, infiltrate the affected tissues, contributing to the inflammatory process. Chikungunya is well known for causing severe joint pain and arthritis. The exact mechanisms underlying joint involvement are not fully understood, but it is believed to involve a combination of direct viral replication in joint tissues and immune-mediated inflammation. The synovial membrane, cartilage, and surrounding tissues can be affected, leading to joint swelling, stiffness, and pain.
The etiology of chikungunya is attributed to the chikungunya virus (CHIKV), which is a single-stranded RNA virus belonging to the Alphavirus genus of the Togaviridae family. The virus is primarily transmitted to humans through the bite of infected mosquitoes, particularly Aedes aegypti and Aedes albopictus species.
The natural transmission cycle of CHIKV involves mosquitoes as the primary vector and vertebrate hosts, including humans, as the reservoirs. The virus is maintained in nature through cycles of mosquito-human-mosquito transmission. Apart from mosquito-borne transmission, other modes of CHIKV transmission have been reported, although they are relatively rare.
These include vertical transmission from infected mother to fetus during pregnancy, transmission through blood transfusion, and laboratory-acquired infections. Chikungunya outbreaks can occur where appropriate mosquito vectors are present, creating favorable conditions for viral transmission. Factors such as high population density, urbanization, inadequate mosquito control measures, and climate change can contribute to chikungunya’s increased risk and spread.
The prognosis of chikungunya is generally good, and most individuals recover fully within weeks to months. Most chikungunya infections do not result in severe complications or long-term health issues.
Clinical History
Many individuals with chikungunya develop a maculopapular rash characterized by small, red spots or bumps on the skin. The rash often starts on the trunk and limbs and may spread to the face and extremities. It is usually itchy and can last for a few days to weeks. Severe joint pain is a hallmark of chikungunya. The pain typically affects multiple joints symmetrically, such as the wrists, fingers, ankles, and knees.
The pain may be debilitating and can last for weeks or months, occasionally becoming chronic. The joints may also appear swollen and tender. Headaches are a frequent symptom of chikungunya and may be severe and debilitating. They can occur in conjunction with fever and other systemic manifestations. Individuals with chikungunya commonly experience fatigue and malaise. Patients may feel exhausted, weak, and have decreased energy.
Physical Examination
Joint tenderness, swelling, and restricted range of motion may be observed during a joint examination. Multiple joints, such as wrists, fingers, ankles, and knees, may be affected symmetrically. The severity of joint involvement can vary, ranging from mild to severe. A maculopapular rash may be present on the skin.
The rash is characterized by small, red spots or bumps that can be itchy and may be distributed on the trunk, limbs, face, and extremities. Palpation of muscles may reveal tenderness, particularly in areas where the patient experiences myalgia. Swollen and tender lymph nodes may be observed during palpation, typically in regions close to the affected joints or the neck area. In some cases, there may be redness and inflammation of the conjunctiva, the thin membrane covering the white part of the eye.
Differential Diagnoses
African tick bite fever
Malaria
Yellow Fever
Measles
Leptospirosis
The primary approach to treating Chikungunya fever focuses on relieving symptoms. This includes ensuring adequate hydration, rest and using medications such as acetaminophen for pain and fever relief. It is important to note that aspirin and most NSAIDs are generally discouraged during the initial 48 hours of symptom onset, as they can potentially worsen platelet dysfunction, mainly if there is a possibility of dengue virus co-infection.
The World Health Organization recommends avoiding these medications during this period. Some studies suggest that low-dose corticosteroid drugs may effectively manage symptoms during the first two months of the post-acute phase. Treatment options for ocular manifestations, such as anterior and posterior uveitis, include topical steroids and cycloplegics. These interventions can help alleviate inflammation and provide relief.
Persistent or recurrent symptoms in the chronic phase of Chikungunya, such as long-lasting joint pain (polyarthralgia), joint inflammation (polyarthritis), and muscle pain (myalgia), have shown positive responses to treatment with hydroxychloroquine when combined with corticosteroids or other disease-modifying anti-rheumatic drugs (DMARDs). Hydroxychloroquine, along with additional medications, helps alleviate these chronic manifestations.
In terms of antiviral treatments, specific antivirals that target viral replication by utilizing small interfering RNAs (siRNAs) and inhibit virus entry and replication have demonstrated promising results. However, it is important to note that these antiviral treatments have yet to receive approval for human use, and further research is needed to establish their safety and effectiveness.
medtigo
Chikungunya
Updated :
September 5, 2023
Chikungunya is a viral disease primarily transmitted to humans by infected female mosquitoes, specifically the Aedes aegypti and Aedes albopictus species. The name “chikungunya” originates from the Kimakonde language, meaning “to become contorted” describing the stooped appearance of individuals suffering from joint pain, a characteristic symptom of the disease.
The chikungunya virus (CHIKV) belongs to the alphavirus genus of the Togaviridae family. It was first identified in Tanzania in 1952 during an outbreak in Makonde village. Since then, chikungunya has spread to many countries in Africa, Asia, Europe, and the Americas.
Chikungunya is considered an endemic disease in several regions of Africa, Asia, and the Indian subcontinent. The virus circulates in these areas, and outbreaks occur periodically. The prevalence of chikungunya can vary from year to year and from region to region within endemic areas. Sporadic or small outbreaks may occur in non-endemic regions due to travel or locally transmitted cases.
Chikungunya outbreaks can result in many cases within a short period. During outbreaks, the incidence can vary widely, ranging from a few cases to thousands or even tens of thousands of cases, depending on the size and vulnerability of the affected population. Chikungunya is generally considered a non-fatal disease; most infected individuals recover fully.
The mortality rate associated with chikungunya is relatively low, especially compared to other mosquito-borne diseases such as dengue or malaria. However, severe cases and complications can occur, particularly among vulnerable populations such as infants, older adults, and individuals with pre-existing health conditions. Mortality rates are typically highest during large-scale outbreaks, and the overall mortality burden remains relatively low compared to other infectious diseases.
Chikungunya virus is primarily transmitted to humans through the bite of infected female mosquitoes. After entering the body, the virus targets and infects the skin, lymphoid tissue, and joint cells. The viral particles bind to specific receptors on the surface of host cells, allowing entry and subsequent replication of the virus. Following the initial infection, the virus can disseminate within the body through the bloodstream, reaching various tissues and organs. This dissemination can lead to systemic symptoms and the involvement of multiple systems.
The immune system plays a crucial role in the pathophysiology of chikungunya. The initial immune response involves the activation of innate immune cells, such as macrophages and dendritic cells, which recognize the viral particles and produce pro-inflammatory cytokines. This immune response helps control viral replication and contributes to the inflammatory process and associated symptoms. The immune response triggers an intense inflammatory reaction characterized by releasing pro-inflammatory mediators and chemokines.
This inflammatory response is responsible for many clinical manifestations observed in chikungunya, such as joint pain, swelling, and fever. The immune cells, and macrophages, infiltrate the affected tissues, contributing to the inflammatory process. Chikungunya is well known for causing severe joint pain and arthritis. The exact mechanisms underlying joint involvement are not fully understood, but it is believed to involve a combination of direct viral replication in joint tissues and immune-mediated inflammation. The synovial membrane, cartilage, and surrounding tissues can be affected, leading to joint swelling, stiffness, and pain.
The etiology of chikungunya is attributed to the chikungunya virus (CHIKV), which is a single-stranded RNA virus belonging to the Alphavirus genus of the Togaviridae family. The virus is primarily transmitted to humans through the bite of infected mosquitoes, particularly Aedes aegypti and Aedes albopictus species.
The natural transmission cycle of CHIKV involves mosquitoes as the primary vector and vertebrate hosts, including humans, as the reservoirs. The virus is maintained in nature through cycles of mosquito-human-mosquito transmission. Apart from mosquito-borne transmission, other modes of CHIKV transmission have been reported, although they are relatively rare.
These include vertical transmission from infected mother to fetus during pregnancy, transmission through blood transfusion, and laboratory-acquired infections. Chikungunya outbreaks can occur where appropriate mosquito vectors are present, creating favorable conditions for viral transmission. Factors such as high population density, urbanization, inadequate mosquito control measures, and climate change can contribute to chikungunya’s increased risk and spread.
The prognosis of chikungunya is generally good, and most individuals recover fully within weeks to months. Most chikungunya infections do not result in severe complications or long-term health issues.
Clinical History
Many individuals with chikungunya develop a maculopapular rash characterized by small, red spots or bumps on the skin. The rash often starts on the trunk and limbs and may spread to the face and extremities. It is usually itchy and can last for a few days to weeks. Severe joint pain is a hallmark of chikungunya. The pain typically affects multiple joints symmetrically, such as the wrists, fingers, ankles, and knees.
The pain may be debilitating and can last for weeks or months, occasionally becoming chronic. The joints may also appear swollen and tender. Headaches are a frequent symptom of chikungunya and may be severe and debilitating. They can occur in conjunction with fever and other systemic manifestations. Individuals with chikungunya commonly experience fatigue and malaise. Patients may feel exhausted, weak, and have decreased energy.
Physical Examination
Joint tenderness, swelling, and restricted range of motion may be observed during a joint examination. Multiple joints, such as wrists, fingers, ankles, and knees, may be affected symmetrically. The severity of joint involvement can vary, ranging from mild to severe. A maculopapular rash may be present on the skin.
The rash is characterized by small, red spots or bumps that can be itchy and may be distributed on the trunk, limbs, face, and extremities. Palpation of muscles may reveal tenderness, particularly in areas where the patient experiences myalgia. Swollen and tender lymph nodes may be observed during palpation, typically in regions close to the affected joints or the neck area. In some cases, there may be redness and inflammation of the conjunctiva, the thin membrane covering the white part of the eye.
Differential Diagnoses
African tick bite fever
Malaria
Yellow Fever
Measles
Leptospirosis
The primary approach to treating Chikungunya fever focuses on relieving symptoms. This includes ensuring adequate hydration, rest and using medications such as acetaminophen for pain and fever relief. It is important to note that aspirin and most NSAIDs are generally discouraged during the initial 48 hours of symptom onset, as they can potentially worsen platelet dysfunction, mainly if there is a possibility of dengue virus co-infection.
The World Health Organization recommends avoiding these medications during this period. Some studies suggest that low-dose corticosteroid drugs may effectively manage symptoms during the first two months of the post-acute phase. Treatment options for ocular manifestations, such as anterior and posterior uveitis, include topical steroids and cycloplegics. These interventions can help alleviate inflammation and provide relief.
Persistent or recurrent symptoms in the chronic phase of Chikungunya, such as long-lasting joint pain (polyarthralgia), joint inflammation (polyarthritis), and muscle pain (myalgia), have shown positive responses to treatment with hydroxychloroquine when combined with corticosteroids or other disease-modifying anti-rheumatic drugs (DMARDs). Hydroxychloroquine, along with additional medications, helps alleviate these chronic manifestations.
In terms of antiviral treatments, specific antivirals that target viral replication by utilizing small interfering RNAs (siRNAs) and inhibit virus entry and replication have demonstrated promising results. However, it is important to note that these antiviral treatments have yet to receive approval for human use, and further research is needed to establish their safety and effectiveness.
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
